Levodopa toxicity and apoptosis

Annals of Neurology

Volumn 44, Issue 3 SUPPL. 1, 1998, Pages

  Melamed, Eldad ^a   Offen, Daniel ^a   Shirvan, Anat ^a   Djaldetti, Ruth ^a   Barzilai, Ari ^b   Ziv, Ilan ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN PEROXIDE; HYDROXYL RADICAL; LEVODOPA; QUINONE DERIVATIVE; SEMIQUINONE; SUPEROXIDE;

APOPTOSIS; CONFERENCE PAPER; HUMAN; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 0031684327     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440722     Document Type: Conference Paper

References (73)

1. Marsden CD. Parkinson's disease. Lancet 1990;335:908-952
2. Agid Y. Parkinson's disease: pathophysiology. Lancet 1991;337: 1321-1324
3. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276:374-379
4. Melamed E, Hefti F, Wurtman RH. Non-aminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 1980;8:528-536
5. Hefti F, Melamed E. L-dopa's mechanism of action in Parkinson's disease. Trends Neurosci 1980;3:229-231
6. Melamed E. Mechanism of action of exogenous L-dopa: Is it a physiological therapy for Parkinson's disease? In: Jankovic J, Tolosa E, eds. Advances in Parkinson's disease and movement disorders. Baltimore: Urban and Schwarzenberg, 1988:87-97
7. Melamed E. Biochemical and functional differences between dopamine formed from endogenous tyrosine and exogenous L-dopa in nigro-striatal dopaminergic neurons. Neurochem Int 1992;20(Suppl):115-117
8. Fahn S. Is levodopa toxic? Neurology 1996;47(Suppl):S184-195
9. Fahn S, Bressman SB. Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984;11:200-206
10. Rajput AH, Stern W, Laverty WH. Chronic low dose levodopa therapy in Parkinson's disease: an argument for delaying L-dopa therapy. Neurology 1984;34:991-996
11. Melamed E. Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. Arch Neurol 1986;43:402-405
12. Quinn NP. A case against early levodopa treatment of Parkinson's disease. Clin Neuropharmacol 1994;17:S43-49
13. Wick MM, Byers L, Frei E. L-dopa: selective toxiciry for melanoma cells in vitro. Science 1977;197:468-469
14. Tanaka M, Sotomatsu A, Kanai H, Hirai S. Dopa and dopamine cause cultured neuronal death in the presence of iron. J Neurol Sci 1991;101:198-203
15. Mena MA, Pardo B, Casarejos MJ, Fahn S, de Yebenes JG. Neurotoxicity of levodopa on catecholamine rich neurons. Mov Disord 1992;7:23-31
16. Graham DJ, Tiffany SM, Bell WR, Gutknecht WF. Autooxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds towards C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978;14:644-653
17. Newcomer TA, Rosenberg PA, Aizenman E. Iron-mediated oxidation of 3,4-dihydroxyphenylalanine to an excitotoxin. J Neurochem 1995;64:1742-1748
18. Graham AG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978;14:633-643
19. Pardo B, Mena MA, Fahn S, de Yebenes JG. Ascorbic acid protecrs against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Mov Disord 1993;8:278-284
20. Mena MA, Pardo B, Paino CL, de Yebenes JG. Levodopa toxicity in fetal rat midbrain neurons in culture: modulation by ascorbic acid. Neuroreport 1993;4:438-440
21. Basma AN, Morris EJ, Nicklas WJ, Geller HM. L-dopa cytotoxicity to PC-12 cells in culture is via its auto-oxidation. J Neurochem 1995;64:825-832
22. Pardo B, Mena MA, Casarejos MJ, Paino CL, de Yebenes JG. Toxic effects of L-dopa in mesencephalic cell cultures: protection with anti-oxidants. Brain Res 1995;682:133-143
23. Li CL, Werner P, Cohen G. Lipid peroxidation in brain: interactions of L-dopa/dopamine with ascorbate and iron. Neurodegeneration 1995;4:147-153
24. Przedborski S, Jackson-Lewis V, Muthane U, et al. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 1993;34:715-723
25. Przedborski S, Jackson-Lewis V, Fahn S. Antiparkinsonian therapies and brain mirochondrial complex I activity. Mov Disord 1995;10:312-317
26. Pardo B, Mena MA, de Yebenes JG. L-dopa inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells. J Neurochem 1995;64:576-582
27. Spencer JP, Jenner A, Arumoa OI, Marsden CD, Halliwell B. Intense oxidative DNA damage promoted by L-dopa and its metabolites: implications for neurodegenerative disease. FEBS Lett 1994;353:246-250
28. Wick MM. Levodopa/dopamine analogs as inhibitors of DNA synthesis in human melanoma cells. J Invest Dermatol 1989; 92:329S-331S
29. Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990;26:428-435
30. Alexander T, Sortwell CE, Sladek CD, Roth RH, Steece-Collier K. Comparison of neurotoxicity following repeated administration of L-dopa, D-dopa and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fischer 344 and Sprague-Dawley donors. Cell Transplant 1997;6:309-315
31. Boobis AR, Fowthrop DJ, Davies DS. Mechanisms of cell death. Trends Pharmacol Sci 1989;10:275-280
32. Martin SJ. Apoptosis: suicide, execution or murder? Trends Cell Biol 1993;3:141-144
33. Cohen JJ. Apoptosis. Immunol Today 1993;14:126-130
34. Ziv I, Melamed E, Nardi N, et al. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - a possible novel pathogentic mechanism in Parkinson's disease. Neurosci Lett 1994;170:136-140
35. Offen D, Ziv I, Gordin S, Malik Z, Barzilai A, Melamed E. Dopamine-induced programmed cell death in mouse thymocytes. Biochim Biophys Acta 1995;1268:171-177
36. Zilkha-Falb R, Ziv I, Nardi N, Offen D, Melamed E, Barzilai A. Monoamine-induced apoptotic neuronal cell death. Cell Mol Neurobiol 1997;7:110-118
37. Offen D, Sternin H, Ziv I, Melamed E, Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implication for treatment of Parkinson's disease. Exp Neurol 1996;141:32-39
38. Ziv I, Offen D, Haviv R, et al. The proto-oncogene bcl-2 inhibits cellular toxicity of dopamine: possible implications for Parkinson's disease. Apoptosis 1997;2:149-155
39. Mochizuki H, Goto K, Mori H, Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 1996; 137:120-123
40. Anglade P, Vyas S, Javoy-Agid F, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histoi Histopathol 1997;12:25-31
41. Tompkins MM, Basgall EJ, Zamvini E, Hill WD. Apoptotic-like changes in Lewy body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol 1997;150:119-131
42. Kosel S, Egensperger R, von Eitzen U, Mehraein P, Graeber MB. On the question of apoptosis in rhe parkinsonian substantia nigra. Acta Neuropathol (Berl) 1997;93:105-108
43. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease. Evidence supporting it. Ann Neurol 1992;32:804-812
44. Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci 1993;16:439-444
45. Jenner P, Dexter DT, Sian J, Schapira AHV, Marsden CD. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann Neurol 1992;32: S82-S87
46. Ziv I, Zilkha-Falb R, Offen D, Shirvan A, Barzilai A, Melamed E. Levodopa induces apoptosis in cultured neuronal cells - a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Mov Disord 1997;12:17-23
47. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC-12 cells by L-dopa. Implications for the treatment of Parkinson's disease. J Clin Invest 1995;95:2458-2464
48. Hefti F, Melamed E, Bhawan J, Wurtman RJ. Long-term administration of L-dopa does not damage dopaminergic neurons in the mouse. Neurology 1981;31:1194-1195
49. Perry TL, Yong VW, Ito U, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-dopa and carbidopa chronically. J Neurochem 1984;43:990-993
50. Naudin B, Bonnet JJ, Costentin J. Acute L-dopa pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigrostriatal dopaminergic neurons in mice. Brain Res 1995;701: 151-157
51. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993;8:129-133
52. Ogawa N, Aganuma M, Kondo Y, Yamamoto M, Mori A. Differential effects of chronic L-dopa treatment on lipid peroxidation in the mouse brain with and without pretreatment with 6-hydroxydopamine. Neurosci Lett 1994;171:55-58
53. Dziewczapolski G, Murer G, Agid Y, Gershanik O, Raisman-Vozari R. Absence of neurotoxicity of chronic L-dopa treatment in 6-hydroxydopamine-lesioned rats. Neuroreport 1997;8:975-979
54. Melamed E, Rosenthal J. Can chronic levodopa therapy accelerate degeneration of dopaminergic neurons and progression of Parkinson's disease? In: Nagatsu T, Fisher A, Yoshida M, eds. Basic clinical and therapeutic aspects of Alzheimer's and Parkinson's diseases. New York: Plenum Press, 1990;253-256
55. Steece-Collier K, Collier TJ, Sladeck CD, Sladeck JR. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons. Exp Neurol 1990;110:201-208
56. 3H-mazindol autoradiography. Neuroscience 1991;43:95-110
57. Melamed E, Rosenthal J, Reches H. Prenatal administration of levodopa is not toxic to fetal dopaminergic neurons in vivo. Neurology 1992;42(Suppl 3):378
58. Quinn N, Parkes D, Janota I, Marsden CD. Preservation of the substantia nigra and locus ceruleus in a patient receiving levodopa (2 kg) plus decarboxylasc inhibitor over a four year period. Mov Disord 1986;1:65-68
59. Rajput AH, Fenton ME, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra? Mov Disord 1997;12:634-638
60. Kordower JH, Freeman TB, Snow BJ, Olanow CW. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995;332:1118-1124
61. Blin J, Bonnet AM, Agid Y. Does levodopa aggravate Parkinson's disease? Neurology 1988;38:1410-1416
62. Isaacs KR, Wolpoe ME, Jacobowitz DM. Calretinin-immunoreactive dopaminergic neurons from embryonic rat mesencephalon are resistant to levodopa-induced neurotoxicity. Exp Neurol 1997;146:25-32
63. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6
64. Munez G, Clarke MF. The bcl-2 family of proteins: regulators of cell death and survival. Trends Cell Biol 1994;4:399-403
65. Offen D, Ziv I, Panet H, Wasserman L, Stein R, Melamed E, Barzilai A. Dopamine-induced apoprosis is inhibited in PC12 cells expressing bcl-2: evidence rhar the proto-oncogene may act as an antioxidant. Cell Mol Neurobiol 1997;17:285-304
66. Mogi M, Harada M, Kondo T, et al. Bcl-2 protein is increased in the brain from parkinsonian patients. Neurosci Lett 1996; 215:137-139
67. Mena MA, Casarejos MJ, Carazo A, Paino CL, de Yebenes GJ. Glia conditioned medium protects fetal rat midbrain neurons in culture from L-dopa toxicity. Neuroreport 1996;7:441-449
68. Olanow CW, Gauger BA, Cederbaum JM. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Ann Neurol 1991;29:556-559
69. Durso R, Evans JE, Josephs E, et al. Central levodopa metabolism in Parkinson's disease after administration of stable isotope-labeled levodopa. Ann Neurol 1997;42:300-304
70. Mytilineou C, Han SK, Cohen G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem 1993; 61:1470-1478
71. Han SK, Mytilineou C, Cohen G. L-dopa upregulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996;66:501-510
72. Ahlskog JE, Uitti RJ, Low PA, Tyce GM, O'Brien JF, Nickander KK. Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease. Neurology 1996;46:796-801
73. Melamed E, Hefti F, Wurtman RJ. Compensatory mechanisms in nigrostriatal dopaminergic system in parkinsonism: studies in an animal model. Israel J Med Sci 1982;18:159-163